"Cytokine storm" in the Phase I trial of monoclonal antibody TGN1412: Better understanding the causes to improve preclinical testing of immunotherapeutics

Journal of Immunology

Volumn 179, Issue 5, 2007, Pages 3325-3331

  Stebbings, Richard ^a   Findlay, Lucy ^a   Edwards, Cherry ^a   Eastwood, David ^a   Bird, Chris ^a   North, David ^a   Mistry, Yogesh ^a   Dilger, Paula ^a   Liefooghe, Emily ^a   Cludts, Isabelle ^a   Fox, Bernard ^a   Tarrant, Gill ^a   Robinson, Jane ^a   Meager, Tony ^a   Dolman, Carl ^a   Thorpe, Susan J ^a   Bristow, Adrian ^a   Wadhwa, Meenu ^a   Thorpe, Robin ^a   Poole, Stephen ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TGN 1412; CYTOKINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TGN1412; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG EFFECT; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNE SYSTEM; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CELL PROLIFERATION; DRUG SCREENING; IMMUNOTHERAPY; MACACA; METABOLISM; METHODOLOGY; MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; CLINICAL TRIALS, PHASE I AS TOPIC; CYTOKINES; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOTHERAPY; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MACACA FASCICULARIS;

EID: 37749032491     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.179.5.3325     Document Type: Article

References (14)

1. Suntharalingam, G., M. R. Perry, S. Ward, S. J. Brett, A. Castello-Cortes, M. D. Brunner, and N. Panoskaltsis. 2006. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355: 1018-1028.
2. 2.6.14. Bacterial endotoxins. 2005. In European Pharmacopoeia, 5th Ed. Council of Europe, Strasbourg, France, pp. 161-165.
3. Poole, S., Y. Mistry, C. Ball, R. E. Gaines Das, L. P. Opie, G. Tucker, and M. Patel. 2003. A rapid 'one-plate' in vitro test for pyrogens. J. Immunol. Methods 274: 209-220.
4. R. E. Gaines Das, P. Brügger, M. Patel, Y. Mistry, and S. Poole. 2004. Monocyte activation test for pro-inflammatory and pyrogenic contaminants of parenteral drugs: test design and data analysis. J. Immunol. Methods 288: 165-177.
5. 2.6.8. Pyrogens. 2005. In European Pharmacopoeia, 5th Ed. Council of Europe, Strasbourg, France, p. 152.
6. 2.6.9. Abnormal toxicity. 2005. In European Pharmacopoeia, 5th Ed. Council of Europe, Strasbourg, France, p. 152.
7. Givan, A. L., J. L. Fisher, M. Waugh, M. S. Ernstoff, and P. K. Wallace. 1999. A flow cytometric method to estimate the precursor frequencies of cells proliferating in response to specific antigens. J. Immunol. Methods 230: 99-112.
8. Rodriguez-Palmero, M., A. Franch, M. Castell, C. Pelegri, F. J. Perez-Cano, C. Kleinschnitz, G. Stoll, T. Hunig, and C. Castellote. 2006. Effective treatment of adjuvant arthritis with a stimulatory CD28-specific monoclonal antibody. J. Rheumatol. 33: 110-118.
9. Beyersdorf, N., T. Hanke, T. Kerkau, and T. Hunig. 2005. Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases. Ann. Rheum. Dis. 64(Suppl. 4): iv91-iv95.
10. Hanke, T. 2006. Lessons from TGN1412. Lancet 368: 1569-1570.
11. Luhder, F., Y. Huang, K. M. Dennehy, C. Guntermann, I. Muller, E. Winkler, T. Kerkau, S. Ikemizu, S. J. Davis, T. Hanke, and T. Hunig. 2003. Topological requirements and signaling properties of T cell-activating, anti-CD28 antibody superagonists. J. Exp. Med. 197: 949-953.
12. Ohresser, M., D. Olive, B. Vanhove, and H. Watier. 2006. Risk in drug trials. Lancet 368: 2205-2206.
13. Kenter, M. J., and A. F. Cohen. 2006. Establishing risk of human experimentation with drugs: lessons from TGN1412. Lancet 368: 1387-1391.
14. Nguyen, D. H., N. Hurtado-Ziola, P. Gagneux, and A. Varki. 2006. Loss of Siglec expression on T lymphocytes during human evolution. Proc. Natl. Acad. Sci. USA 103: 7765-7770.